Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response

Infection and Immunity

Volumn 83, Issue 2, 2015, Pages 591-603

  Ramos Sevillano, Elisa ^a,b,c,h   Urzainqui, Ana ^d   Campuzano, Susana ^e   Moscoso, Miriam ^a,b,i   González Camacho, Fernando ^c   Domenech, Mirian ^a,b   de Córdoba, Santiago Rodríguez ^a,f   Sánchez Madrid, Francisco ^d   Brown, Jeremy S ^g   García, Ernesto ^a,b   Yusteb, Jose ^b,c  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AMIDASE; AMIDASE LYTA; AUTOLYSIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4BP; COMPLEMENT FACTOR H; PNEUMOLYSIN; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; C4BP PROTEIN, MOUSE; HISTOCOMPATIBILITY ANTIGEN; N ACETYLMURAMOYLALANINE AMIDASE; PHOSPHORYLCHOLINE; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; SPSA PROTEIN, STREPTOCOCCUS PNEUMONIAE; STREPTOLYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE MICROSCOPY; MACROPHAGE; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; OPSONIZATION; PATHOGENESIS; PHAGOCYTOSIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; SEPSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; WESTERN BLOTTING; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTERIAL CAPSULE; C57BL MOUSE; CELL WALL; ENZYMOLOGY; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PNEUMOCOCCAL INFECTION;

ANIMALS; BACTERIAL CAPSULES; BACTERIAL PROTEINS; CELL WALL; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT FACTOR H; HISTOCOMPATIBILITY ANTIGENS; HOST-PATHOGEN INTERACTIONS; MICE; MICE, INBRED C57BL; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; PHAGOCYTOSIS; PHOSPHORYLCHOLINE; PNEUMOCOCCAL INFECTIONS; POLYSACCHARIDES, BACTERIAL; SEPSIS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS;

EID: 84921370338     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02811-14     Document Type: Article

References (56)

1. Bogaert D, De Groot R, Hermans PWM. 2004. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144-154. http://dx.doi.org/10.1016/S1473-3099(04)00938-7.
2. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, for the Hib and Pneumococcal Global Burden of Disease Study Team. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893-902. http://dx.doi.org/10.1016/S0140-6736(09)61204-6.
3. Kadioglu A, Weiser JN, Paton JC, Andrew PW. 2008. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6:288-301. http://dx.doi.org/10.1038/nrmicro1871.
4. van der Poll T, Opal SM. 2009. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374:1543-1556. http://dx.doi.org/10.1016/S0140-6736(09)61114-4.
5. Xu Y, Ma M, Ippolito GC, Schroeder HW, Jr, Carroll MC, Volanakis JE. 2001. Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A 98:14577-14582. http://dx.doi.org/10.1073/pnas.261428398.
6. Brown JS, Hussell T, Gilliland SM, Holden DW, Paton JC, Ehrenstein MR, Walport MJ, Botto M. 2002. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A 99:16969-16974. http://dx.doi.org/10.1073/pnas.012669199.
7. Ali YM, Lynch NJ, Haleem KS, Fujita T, Endo Y, Hansen S, Holmskov U, Takahashi K, Stahl GL, Dudler T, Girija UV, Wallis R, Kadioglu A, Stover CM, Andrew PW, Schwaeble WJ. 2012. The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. PLoS Pathog 8:e1002793. http://dx.doi.org/10.1371/journal.ppat.1002793.
8. Yuste J, Sen A, Truedsson L, Jönsson G, Tay LS, Hyams C, Baxendale HE, Goldblatt F, Botto M, Brown JS. 2008. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun 76:3761-3770. http://dx.doi.org/10.1128/IAI.00291-08.
9. Kang YS, Do Y, Lee HK, Park SH, Cheong C, Lynch RM, Loeffler JM, Steinman RM, Park CG. 2006. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell 125:47-58. http://dx.doi.org/10.1016/j.cell.2006.01.046.
10. Yuste J, Botto M, Bottoms SE, Brown JS. 2007. Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog 3:1208-1219. http://dx.doi.org/10.1371/journal.ppat.0030120.
11. Walport MJ. 2001. Complement. First of two parts. N Engl J Med 344:1058-1066. http://dx.doi.org/10.1056/NEJM200104053441406.
12. Walport MJ. 2001. Complement. Second of two parts. N Engl J Med 344:1140-1144. http://dx.doi.org/10.1056/NEJM200104123441506.
13. Lambris JD, Ricklin D, Geisbrecht BV. 2008. Complement evasion by human pathogens. Nat Rev Microbiol 6:132-142. http://dx.doi.org/10.1038/nrmicro1824.
14. Agarwal V, Hammerschmidt S, Malm S, Bergmann S, Riesbeck K, Blom AM. 2012. Enolase of Streptococcus pneumoniae binds human complement inhibitor C4b-binding protein and contributes to complement evasion. J Immunol 189:3575-3584. http://dx.doi.org/10.4049/jimmunol.1102934.
15. Dieudonné-Vatran A, Krentz S, Blom AM, Meri S, Henriques-Normark B, Riesbeck K, Albiger B. 2009. Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J Immunol 182:7865-7877. http://dx.doi.org/10.4049/jimmunol.0802376.
16. 2+-dependent repressor AdcR and inhibit complement deposition through the recruitment of complement factor H. FASEB J 23:731-738. http://dx.doi.org/10.1096/fj.08-119537.
17. Dave S, Brooks-Walter A, Pangburn MK, McDaniel LS. 2001. PspC, a pneumococcal surface protein, binds human factor H. Infect Immun 69:3435-3437. http://dx.doi.org/10.1128/IAI.69.5.3435-3437.2001.
18. Yuste J, Khandavilli S, Ansari N, Muttardi K, Ismail L, Hyams C, Weiser J, Mitchell T, Brown JS. 2010. The effects of PspC on complement-mediated immunity to Streptococcus pneumoniae vary with strain background and capsular serotype. Infect Immun 78:283-292. http://dx.doi.org/10.1128/IAI.00541-09.
19. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. 2010. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 78:704-715. http://dx.doi.org/10.1128/IAI.00881-09.
20. Tilley SJ, Orlova EV, Gilbert RJC, Andrew PW, Saibil HR. 2005. Structural basis of pore formation by the bacterial toxin pneumolysin. Cell 121:247-256. http://dx.doi.org/10.1016/j.cell.2005.02.033.
21. Yuste J, Botto M, Paton JC, Holden DW, Brown JS. 2005. Additive inhibition of complement deposition by pneumolysin and PspA facilitates Streptococcus pneumoniae septicemia. J Immunol 175:1813-1819. http://dx.doi.org/10.4049/jimmunol.175.3.1813.
22. Price KE, Camilli A. 2009. Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J Bacteriol 191:2163-2168. http://dx.doi.org/10.1128/JB.01489-08.
23. Fernández-Tornero C, López R, García E, Giménez-Gallego G, Romero A. 2001. A novel solenoid fold in the cell wall anchoring domain of the pneumococcal virulence factor LytA. Nat Struct Biol 8:1020-1024. http://dx.doi.org/10.1038/nsb724.
24. Canvin JR, Marvin AP, Sivakumaran M, Paton JC, Boulnois GJ, Andrew PW, Mitchell TJ. 1995. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis 172:119-123. http://dx.doi.org/10.1093/infdis/172.1.119.
25. Moscoso M, Domenech M, García E. 2010. Vancomycin tolerance in clinical and laboratory Streptococcus pneumoniae isolates depends on reduced enzyme activity of the major LytA autolysin or cooperation between CiaH histidine kinase and capsular polysaccharide. Mol Microbiol 77:1052-1064. http://dx.doi.org/10.1111/j.1365-2958.2010.07271.x.
26. Ramos-Sevillano E, Rodríguez-Sosa C, Díez-Martínez R, Giménez MJ, Olmedillas E, García P, García E, Aguilar L, Yuste J. 2012. Macrolides and -lactam antibiotics enhance C3b deposition on the surface of multidrug-resistant Streptococcus pneumoniae strains by a LytA autolysindependent mechanism. Antimicrob Agents Chemother 56:5534-5540. http://dx.doi.org/10.1128/AAC.01470-12.
27. Ramos-Sevillano E, Moscoso M, García P, Garciía E, Yuste J. 2011. Nasopharyngeal colonization and invasive disease are enhanced by the cell wall hydrolases LytB and LytC of Streptococcus pneumoniae. PLoS One 6:e23626. http://dx.doi.org/10.1371/journal.pone.0023626.
28. Domenech M, Ramos-Sevillano E, García E, Moscoso M, Yuste J. 2013. Biofilm formation avoids complement immunity and phagocytosis of Streptococcus pneumoniae. Infect Immun 81:2606-2615. http://dx.doi.org/10.1128/IAI.00491-13.
29. Mellroth P, Sandalova T, Kikhney A, Vilaplana F, Hesek D, Lee M, Mobashery S, Normark S, Svergun D, Henriques-Normark B, Achour A. 2014. Structural and functional insights into peptidoglycan access for the lytic amidase LytA of Streptococcus pneumoniae. mBio 5(1):e01120-13. http://dx.doi.org/10.1128/mBio.01120-13.
30. García JL, García E, López R. 1987. Overproduction and rapid purification of the amidase of Streptococcus pneumoniae. Arch Microbiol 149:52-56. http://dx.doi.org/10.1007/BF00423136.
31. Alcorlo M, Tortajada A, Rodríguez de Córdoba S, Llorca O. 2013. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc Natl Acad Sci U S A 110:13504-13509. http://dx.doi.org/10.1073/pnas.1309618110.
32. Alcorlo M, Martínez-Barricarte R, Fernández FJ, Rodríguez-Gallego C, Round A, Vega MC, Harris CL, de Córdoba SR, Llorca O. 2011. Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopy. Proc Natl Acad Sci U S A 108:13236-13240. http://dx.doi.org/10.1073/pnas.1106746108.
33. Morey P, Cano V, Martí-Lliteras P, López-Goómez A, Regueiro V, Saus C, Bengoechea JA, Garmendia J. 2011. Evidence for a non-replicative intracellular stage of nontypable Haemophilus influenzae in epithelial cells. Microbiology 157:234-250. http://dx.doi.org/10.1099/mic.0.040451-0.
34. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4:415-422.
35. Domenech M, García E, Moscoso M. 2009. Versatility of the capsular genes during biofilm formation by Streptococcus pneumoniae. Environ Microbiol 11:2542-2555. http://dx.doi.org/10.1111/j.1462-2920.2009.01979.x.
36. Blumenkrantz N, Asboe-Hansen G. 1973. New method for quantitative determination of uronic acids. Anal Biochem 54:484-489. http://dx.doi.org/10.1016/0003-2697(73)90377-1.
37. Agarwal V, Sroka M, Fulde M, Bergmann S, Riesbeck K, Blom AM. 2014. Binding of Streptococcus pneumoniae endopeptidase O (PepO) to complement component C1q modulates the complement attack and promotes host cell adherence. J Biol Chem 289:15833-15844. http://dx.doi.org/10.1074/jbc.M113.530212.
38. Underhill DM, Goodridge HS. 2012. Information processing during phagocytosis. Nat Rev Immunol 12:492-502. http://dx.doi.org/10.1038/nri3244.
39. Dalia AB, Weiser JN. 2011. Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody. Cell Host Microbe 10:486-496. http://dx.doi.org/10.1016/j.chom.2011.09.009.
40. Koedel U, Scheld WM, Pfister HW. 2002. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2:721-736. http://dx.doi.org/10.1016/S1473-3099(02)00450-4.
41. Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI. 2004. Tissuespecific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis 190:1661-1669. http://dx.doi.org/10.1086/424596.
42. Hirst RA, Gosai B, Rutman A, Guerin CJ, Nicotera P, Andrew PW, O'Callaghan C. 2008. Streptococcus pneumoniae deficient in pneumolysin or autolysin has reduced virulence in meningitis. J Infect Dis 197:744-751. http://dx.doi.org/10.1086/527322.
43. Berry AM, Paton JC. 2000. Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun 68:133-140. http://dx.doi.org/10.1128/IAI.68.1.133-140.2000.
44. Berry AM, Paton JC, Hansman D. 1992. Effect of insertional inactivation of the genes encoding pneumolysin and autolysin on the virulence of Streptococcus pneumoniae type 3. Microb Pathog 12:87-93. http://dx.doi.org/10.1016/0882-4010(92)90111-Z.
45. Kharat AS, Tomasz A. 2006. Drastic reduction in the virulence of Streptococcus pneumoniae expressing type 2 capsular polysaccharide but lacking choline residues in the cell wall. Mol Microbiol 60:93-107. http://dx.doi.org/10.1111/j.1365-2958.2006.05082.x.
46. Paton JC, Rowan-Kelly B, Ferrante A. 1984. Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun 43:1085-1087.
47. Alcantara RB, Preheim LC, Gentry-Nielsen MJ. 2001. Pneumolysininduced complement depletion during experimental pneumococcal bacteremia. Infect Immun 69:3569-3575. http://dx.doi.org/10.1128/IAI.69.6.3569-3575.2001.
48. Angel CS, Ruzek M, Hostetter MK. 1994. Degradation of C3 by Streptococcus pneumoniae. J Infect Dis 170:600-608. http://dx.doi.org/10.1093/infdis/170.3.600.
49. Briles DE, Claflin JL, Schroer K, Forman C. 1981. Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 294:88-90. http://dx.doi.org/10.1038/294088a0.
50. Briles DE, Forman C, Horowitz JC, Volanakis JE, Benjamin WH, Jr, McDaniel LS, Eldridge J, Brooks J. 1989. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun 57:1457-1464.
51. Li J, Szalai AJ, Hollingshead SK, Nahm MH, Briles DE. 2009. Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages. Infect Immun 77:464-471. http://dx.doi.org/10.1128/IAI.00892-08.
52. Standish AJ, Weiser JN. 2009. Human neutrophils kill Streptococcus pneumoniae via serine proteases. J Immunol 183:2602-2609. http://dx.doi.org/10.4049/jimmunol.0900688.
53. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. 2010. Neutrophil kinetics in health and disease. Trends Immunol 31:318-324. http://dx.doi.org/10.1016/j.it.2010.05.006.
54. Dalia AB, Standish AJ, Weiser JN. 2010. Three surface exoglycosidases from Streptococcus pneumoniae, NanA, BgaA, and StrH, promote resistance to opsonophagocytic killing by human neutrophils. Infect Immun 78:2108-2116. http://dx.doi.org/10.1128/IAI.01125-09.
55. Martner A, Skovbjerg S, Paton JC, Wold AE. 2009. Streptococcus pneumoniae autolysis prevents phagocytosis and production of phagocyteactivating cytokines. Infect Immun 77:3826-3837. http://dx.doi.org/10.1128/IAI.00290-09.
56. Stuart LM, Ezekowitz RA. 2005. Phagocytosis: elegant complexity. Immunity 22:539-550. http://dx.doi.org/10.1016/j.immuni.2005.05.002.